Wenxiu Yao

机构：University of Electronic Science and Technology of China, Sichuan Cancer Hospital · ORCID：0009-0008-0812-5656

发表论文 95 篇 · 总被引 2675 次 · h-index 24

代表论文

• Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer (2024 · New England Journal of Medicine · 被引 223)
• KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. (2024 · Journal of Clinical Oncology · 被引 72)
• Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study (2024 · The Lancet Oncology · 被引 61)
• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial (2025 · The Lancet · 被引 50)
• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)